Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2003

View Archived Issues

New data on memantine in moderate to severe Alzheimer's disease

Intracellular fate of NB-1011 characterized by NewBiotics scientists

Optimization of farnesyltransferase inhibitors described at ACS by Pharmacopeia

RXR modulators as novel therapies for type 2 diabetes

Probiodrug presents DPP-I inhibitors for use in cancer and other diseases

New series of platelet ADP receptor inhibitors identified at Millennium

Antitumor duocarmycin analogues claimed by researchers at Scripps Research Institute

Euroceltique scientists prepare and test novel sodium channel blockers

New NPY Y5 receptor modulators in early development at AstraZeneca

Roche presents new CCR3 receptor antagonists and their use in asthma therapy

Data safety monitoring board recommends continuation of Fibrillex phase II/III trial

New Rapamune indication approved

StemCells granted patent for methods of isolating pancreatic progenitor cells

Affitech and NatImmune collaborate in colon cancer

Phase I IND amendment for Oxycyte submitted

Alizyme completes enrollment of phase IIb trial of renzapride

AG-858/Gleevec combination therapy subject of new phase II trial in CML

Tolvaptan shows no signs of drug interactions with warfarin or amiodarone

Efficacy results reported from pilot phase IIa study of DB-289 in pneumonia

FDA lifts clinical hold on trials of MacroChem's SEPA-based drugs

OSI updates Tarceva program progress

Pharmacokinetics and metabolism of bazedoxifene assessed in postmenopausal women

Orally active, nonemetogenic PDE4 inhibitor shows respiratory antiinflammatory activity

AWD-33-159: a structurally and mechanistically novel anticonvulsant

Macrocyclic thrombin inhibitors with high potency and selectivity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...